JP2020531514A - 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節 - Google Patents

終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節 Download PDF

Info

Publication number
JP2020531514A
JP2020531514A JP2020511214A JP2020511214A JP2020531514A JP 2020531514 A JP2020531514 A JP 2020531514A JP 2020511214 A JP2020511214 A JP 2020511214A JP 2020511214 A JP2020511214 A JP 2020511214A JP 2020531514 A JP2020531514 A JP 2020531514A
Authority
JP
Japan
Prior art keywords
receptor
rage
gpcr
modulator
coexisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020511214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531514A5 (https=
Inventor
プレーガー，ケヴィン・ドナルド・ジョージ
トーマス，マーリン・クリストファー
ピカリング，レイリーン・ジェイン
ロサド，カルロス
ティケリス，クリストス
Original Assignee
モナシュ・ユニヴァーシティ
ザ・ユニヴァーシティ・オヴ・ウェスタン・オーストラリア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017903381A external-priority patent/AU2017903381A0/en
Application filed by モナシュ・ユニヴァーシティ, ザ・ユニヴァーシティ・オヴ・ウェスタン・オーストラリア filed Critical モナシュ・ユニヴァーシティ
Publication of JP2020531514A publication Critical patent/JP2020531514A/ja
Publication of JP2020531514A5 publication Critical patent/JP2020531514A5/ja
Priority to JP2023121818A priority Critical patent/JP2023156353A/ja
Priority to JP2025227130A priority patent/JP2026062654A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
JP2020511214A 2017-08-22 2018-08-21 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節 Pending JP2020531514A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023121818A JP2023156353A (ja) 2017-08-22 2023-07-26 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
JP2025227130A JP2026062654A (ja) 2017-08-22 2025-12-03 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2017903381 2017-08-22
AU2017903381A AU2017903381A0 (en) 2017-08-22 Screening Assays, Modulators and Modulation of Activation of Receptor For Advanced Glycation End-Products (RAGE)
AU2018902298 2018-06-26
AU2018902298A AU2018902298A0 (en) 2018-06-26 Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE)
PCT/AU2018/050883 WO2019036753A1 (en) 2017-08-22 2018-08-21 SCREENING TESTS, MODULATORS AND MODULATION OF RECEIVER ACTIVATION FOR ADVANCED GLYCATION TERMINAL PRODUCTS (RAGE)

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023121818A Division JP2023156353A (ja) 2017-08-22 2023-07-26 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
JP2025227130A Division JP2026062654A (ja) 2017-08-22 2025-12-03 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節

Publications (2)

Publication Number Publication Date
JP2020531514A true JP2020531514A (ja) 2020-11-05
JP2020531514A5 JP2020531514A5 (https=) 2021-09-30

Family

ID=65438276

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020511214A Pending JP2020531514A (ja) 2017-08-22 2018-08-21 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
JP2023121818A Pending JP2023156353A (ja) 2017-08-22 2023-07-26 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
JP2025227130A Pending JP2026062654A (ja) 2017-08-22 2025-12-03 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023121818A Pending JP2023156353A (ja) 2017-08-22 2023-07-26 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
JP2025227130A Pending JP2026062654A (ja) 2017-08-22 2025-12-03 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節

Country Status (7)

Country Link
US (2) US12060408B2 (https=)
EP (1) EP3672982A4 (https=)
JP (3) JP2020531514A (https=)
CN (2) CN120607606A (https=)
AU (1) AU2018322482B2 (https=)
CA (1) CA3109871A1 (https=)
WO (1) WO2019036753A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023084477A (ja) * 2021-12-07 2023-06-19 花王株式会社 硫黄化合物を原因とするにおいの抑制剤の評価及び／又は選択方法
WO2023200122A1 (ko) * 2022-04-15 2023-10-19 아주대학교산학협력단 Rage 길항제 및 age 소거제를 포함하는 당뇨성 뇌졸중 예방 또는 치료용 약학적 조성물
JP2023156353A (ja) * 2017-08-22 2023-10-24 モナシュ・ユニヴァーシティ 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102203850B1 (ko) * 2019-04-09 2021-01-18 사회복지법인 삼성생명공익재단 신경교종의 진단 또는 예후 예측용 조성물 및 이에 관한 정보를 제공하는 방법
CN116249787A (zh) 2020-06-22 2023-06-09 雷杰纳荣制药公司 用g蛋白偶联受体75(gpr75)抑制剂治疗肥胖症
WO2022150709A1 (en) * 2021-01-11 2022-07-14 President And Fellows Of Harvard College Compositions and methods for treating viral infection
CN113293212A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用
CN113789379B (zh) * 2021-08-30 2022-08-23 远见生物科技（上海）有限公司 一种检测前列腺癌的诊断试剂盒及其检测方法与应用
WO2024044659A1 (en) * 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Constitutively active g protein-coupled receptor compositions and methods of use thereof
CN118777620A (zh) * 2023-04-07 2024-10-15 浙江友宁生物医药科技有限公司 Gpr139受体激活检测方法、生理功能评价方法及应用
CN116410335B (zh) * 2023-04-24 2024-08-13 徐州医科大学 一种多肽tat-mrgprx1c及其应用
CN118755834B (zh) * 2024-07-15 2025-11-18 河北医科大学第四医院（河北省肿瘤医院） 胃癌复发预测模型
CN119901926A (zh) * 2025-03-31 2025-04-29 浙江省立同德医院(浙江省精神卫生研究院) 一种基于rage过表达和spr技术的rage靶向药物筛选方法
CN121695261B (zh) * 2026-02-11 2026-04-17 湖南启元生物科技有限公司 一种蛋白组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008537877A (ja) * 2005-03-17 2008-10-02 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Ｒａｇｅ／ｄｉａｐｈａｎｏｕｓ相互作用および関連する組成物および方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5004687A (en) 1985-05-21 1991-04-02 University Of Georgia Research Foundation, Inc. Insect virus vector with broadened host range
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
WO1990009441A1 (en) 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
EP1285967A3 (en) 1990-09-21 2005-03-02 Chiron Corporation Human retroviral packaging cell line
DE69131908T3 (de) 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz, Joseph R. Phasenmodulationsenergieübertragungsfluoroimmunassay
AU3972893A (en) 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
US6130074A (en) 1992-06-01 2000-10-10 American Cyanamid Company Five Giralda Farms Recombinant insect virus with reduced capacity for host-to-host transmission in the environment and methods to produce said virus
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
JP3147514B2 (ja) 1992-07-08 2001-03-19 住友電装株式会社 電線送給装置
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
WO1994023048A2 (en) 1993-04-06 1994-10-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gibbon ape leukemia virus-based retroviral vectors
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US6120764A (en) 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
US6140087A (en) 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
EP0728202A4 (en) 1993-11-12 1997-04-23 Univ Case Western Reserve EPISOMIC EXPRESSION VECTOR FOR HUMAN GENE THERAPY
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
ES2267101T3 (es) 1994-04-29 2007-03-01 PHARMACIA & UPJOHN COMPANY LLC Vacuna contra virus de inmunodeficiencia felina.
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5662897A (en) 1994-07-27 1997-09-02 U. Of Ga Research Foundation Insect viruses, sequences, insecticidal compositions and methods of use
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
GB9506782D0 (en) 1995-04-01 1995-05-24 British Biotech Pharm Retroviral vectors
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
AU722196B2 (en) 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
JP2000506727A (ja) 1996-03-05 2000-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 組換え生ネコ免疫不全ウイルスおよびプロウイルスｄｎａワクチン
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6143565A (en) 1997-08-22 2000-11-07 The United States Of America As Represented By The Secretary Of Agriculture Stable insect virus-cell expression system
US6893827B1 (en) 2000-02-07 2005-05-17 Applera Corporation Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation
NZ526720A (en) 2000-12-28 2007-11-30 Altus Pharmaceuticals Inc Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
WO2003008446A1 (fr) 2001-07-19 2003-01-30 Mitsubishi Pharma Corporation Polypeptides se rapportant au transfert de signaux de recepteur de produits terminaux a glycation avancee
JP4734498B2 (ja) 2003-07-09 2011-07-27 ライフ テクノロジーズ コーポレイション タンパク質−タンパク質相互作用を解析する方法
US7488583B2 (en) 2003-09-25 2009-02-10 Odyssey Thera, Inc. Fragment complementation assays for G-protein-coupled receptors and their signaling pathways
JP5188804B2 (ja) 2004-08-03 2013-04-24 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質及びその使用方法
KR100859972B1 (ko) 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드
MX2008012023A (es) 2006-03-21 2008-10-01 Wyeth Corp Metodos para prevenir y tratar enfermedades amiloidogenicas.
DK2080012T3 (da) 2006-11-10 2013-06-17 Dimerix Bioscience Pty Ltd Fremgangsmåder til analyse af testforbindelser på forbundne receptorer.
US20100249038A1 (en) 2007-06-12 2010-09-30 Board Of Regents, University Of Texas System Antagonists of the receptor for advanced glycation end-products (rage)
US8101373B2 (en) 2007-10-12 2012-01-24 Discoverx Corporation β-galactosidase donor fragments
WO2012109569A1 (en) 2011-02-11 2012-08-16 The Trustees Of Columbia University In The City Of New York The receptor for advanced glycation endproducts (rage) is a receptor for lysophosphatidic acid (lpa)
AU2012260434A1 (en) 2011-05-23 2013-10-31 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
JP2014527180A (ja) 2011-09-14 2014-10-09 アベテルノ リミテッド 細胞内細胞選別
JP2020531514A (ja) * 2017-08-22 2020-11-05 モナシュ・ユニヴァーシティ 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008537877A (ja) * 2005-03-17 2008-10-02 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Ｒａｇｅ／ｄｉａｐｈａｎｏｕｓ相互作用および関連する組成物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 32, JPN6022030622, 9 August 2013 (2013-08-09), pages 938 - 944, ISSN: 0005155512 *
SCIENTIFIC REPORTS, vol. Vol. 6, Article number: 22450, JPN6022030624, 3 March 2016 (2016-03-03), ISSN: 0005155513 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023156353A (ja) * 2017-08-22 2023-10-24 モナシュ・ユニヴァーシティ 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
JP2023084477A (ja) * 2021-12-07 2023-06-19 花王株式会社 硫黄化合物を原因とするにおいの抑制剤の評価及び／又は選択方法
WO2023200122A1 (ko) * 2022-04-15 2023-10-19 아주대학교산학협력단 Rage 길항제 및 age 소거제를 포함하는 당뇨성 뇌졸중 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
CN120607606A (zh) 2025-09-09
CN111247163A (zh) 2020-06-05
WO2019036753A1 (en) 2019-02-28
EP3672982A4 (en) 2021-06-09
CA3109871A1 (en) 2019-02-28
AU2018322482A1 (en) 2020-04-02
JP2026062654A (ja) 2026-04-10
US20250019415A1 (en) 2025-01-16
CN111247163B (zh) 2024-11-26
US12060408B2 (en) 2024-08-13
AU2018322482B2 (en) 2024-04-04
JP2023156353A (ja) 2023-10-24
EP3672982A1 (en) 2020-07-01
US20200207836A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
US20250019415A1 (en) Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE)
Palty et al. SARAF inactivates the store operated calcium entry machinery to prevent excess calcium refilling
Kawabe et al. ELKS1 localizes the synaptic vesicle priming protein bMunc13-2 to a specific subset of active zones
Danser The role of the (pro) renin receptor in hypertensive disease
Doan et al. Biochemical and pharmacological characterization of nuclear urotensin‐II binding sites in rat heart
AU2017342028A1 (en) Methods for screening for modulators of GDF15-like biological activity
Wang et al. Hepatic and cardiac beneficial effects of a long‐acting Fc‐apelin fusion protein in diet‐induced obese mice
WO2016168594A1 (en) Sensor systems for target ligands and uses thereof
Liao et al. Alternative splicing generates a novel truncated Cav1. 2 channel in neonatal rat heart
Guo et al. The super elongation complex (SEC) mediates phase transition of SPT5 during transcriptional pause release
US20230235084A1 (en) Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases
Nilsson et al. Somatostatin triggers local cAMP and Ca2+ signaling in primary cilia to modulate pancreatic β-cell function
Douchez et al. Design, synthesis, and biological assessment of biased allosteric modulation of the urotensin II receptor using achiral 1, 3, 4-Benzotriazepin-2-one turn mimics
Billard et al. Discovery of new allosteric modulators of the urotensinergic system through substitution of the urotensin II-related peptide (URP) phenylalanine residue
Morita et al. Autophagy protects against human islet amyloid polypeptide‐associated apoptosis
US20220169693A1 (en) Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules
Hung et al. Poly-alanine-tailing is a modifier of neurodegeneration caused by Listerin mutation
US20250282849A1 (en) Fndc4 fusion protein and uses thereof
WO2001040797A1 (fr) Procede de criblage
Delaitre et al. Synthesis and pharmacological characterization of fluorescent ligands targeting the angiotensin II receptors derived from agonists, β-arrestin-biased agonists, and antagonists
Fakhfouri Interventions pharmacologiques affectants spécifiquement la signalisation du récepteur D2 de la dopamine médiée par la beta arrestine 2
Miller Identification of potent and selective inhibitors of the epithelial sodium channel d
JP2001309792A (ja) スクリーニング方法
HK40080737A (en) Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases
Lvov et al. 38 Single transmembrane regulatory subunits of voltage-gated potassium channels

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210820

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230731

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230818

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227